Clinical significance of epithelial-mesenchymal transition-associated markers in malignant pleural mesothelioma

Oncology (Switzerland)

Volumn 86, Issue 2, 2014, Pages 109-116

  Iwanami, Takashi ^a   Uramoto, Hidetaka ^a   Nakagawa, Makoto ^a   Shimokawa, Hidehiko ^a   Yamada, Sohsuke ^b   Kohno, Kimitoshi ^a   Tanaka, Fumihiro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b Department of Pathology and Cell Biology ^*  (Japan)

Author keywords

Catenin; Epithelial mesenchymal transition; Malignant pleural mesothelioma; Prognosis; Twist

Indexed keywords

AGED; CADHERINS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FIBRONECTINS; GAMMA CATENIN; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MULTIVARIATE ANALYSIS; NUCLEAR PROTEINS; PLEURAL NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TWIST TRANSCRIPTION FACTOR; VIMENTIN; Y-BOX-BINDING PROTEIN 1;

BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; FIBRONECTIN; GEMCITABINE; NAVELBINE; PEMETREXED; PLAKOGLOBIN; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; VIMENTIN; Y BOX BINDING PROTEIN 1;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SARCOMA; STATISTICAL ANALYSIS; SURVIVAL RATE;

EID: 84892754006     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000356874     Document Type: Article

References (36)

1. Sharif S, Zahid I, Routledge T, Scarci M: Extrapleural pneumonectomy or supportive care: treatment of malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg 2011; 12: 1040-1045.
2. van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P: Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol 2011; 78: 92-111.
3. Hiddinga BI, Van Meerbeeck JP: Surgery in mesothelioma. J Thorac Oncol 2013; 8: 525-529.
4. Travis WD, Brambilla E, Muller-Hermelink H, Harris CC (eds): Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, IARC Press, 2004, pp 125-144.
5. Milano MT, Zhang H: Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol 2010; 5: 1841-1848.
6. Ordonez NG: Pleomorphic mesothelioma: report of 10 cases. Mod Pathol 2012; 25: 1011-1022.
7. Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
8. Schramm A, Opitz I, Thies S, Seifert B, Moch H, Weder W, et al: Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. Eur J Cardiothorac Surg 2010; 37: 566-572.
9. Fassina A, Cappellesso R, Guzzardo V, Dalla Via L, Piccolo S, Ventura L, et al: Epithelialmesenchymal transition in malignant mesothelioma. Mod Pathol 2012; 25: 86-99.
10. Merikallio H, Paakko P, Salmenkivi K, Kinnula V, Harju T, Soini Y: Expression of snail, twist, and Zeb1 in malignant mesothelioma. APMIS 2013; 121: 1-10.
11. Casarsa C, Bassani N, Ambrogi F, Zabucchi G, Boracchi P, Biganzoli E, et al: Epithelial-tomesenchymal transition, cell polarity and stemness-associated features in malignant pleural mesothelioma. Cancer Lett 2011; 302: 136-143.
12. Evdokimova V, Tognon C, Ng T, Sorensen PH: Reduced proliferation and enhanced migration: two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1. Cell Cycle 2009; 8: 2901-2906.
13. Rusch VW: A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995; 108: 1122-1128.
14. Uramoto H, Iwata T, Onitsuka T, Shimokawa H, Hanagiri T, Oyama T: Epithelial mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res 2010; 30: 2513-2517.
15. Yoshimatsu T, Uramoto H, Oyama T, Yashima Y, Gu C, Morita M, et al: Y-box-binding protein-1 expression is not correlated with p53 expression but with proliferating cell nuclear antigen expression in non-small cell lung cancer. Anticancer Res 2005; 25: 3437-3443.
16. Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K, et al: Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 2010; 68: 198-203.
17. Lee YC, Wu CT, Chen CS, Hsu HH, Chang YL: The significance of E-cadherin and α-, β-, and γ-catenin expression in surgically treated nonsmall cell lung cancers of 3 cm or less in size. J Thorac Cardiovasc Surg 2002; 123: 502-507.
18. Soini Y, Tuhkanen H, Sironen R, Virtanen I, Kataja V, Auvinen P, et al: Transcription factors zeb1, twist and snai1 in breast carcinoma. BMC Cancer 2011; 11: 73.
19. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et al: Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-1616.
20. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, et al: Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353: 1564-1573.
21. Surmont VF, van Thiel ER, Vermaelen K, van Meerbeeck JP: Investigational approaches for mesothelioma. Front Oncol 2011; 1: 22.
22. Yamashita T, Uramoto H, Onitsuka T, Ono K, Baba T, So T, et al: Association between lymphangiogenesis-/micrometastasis-and adhesion-related molecules in resected stage I NSCLC. Lung Cancer 2010; 70: 320-328.
23. Maeda O, Usami N, Kondo M, Takahashi M, Goto H, Shimokata K, et al: Plakoglobin (gamma-catenin) has TCF/LEF family-dependent transcriptional activity in betacatenin-deficient cell line. Oncogene 2004; 23: 964-972.
24. Winn RA, Bremnes RM, Bemis L, Franklin WA, Miller YE, Cool C, Heasley LE: Gamma-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene 2002; 21: 7497-7506.
25. Shibata K, Kajiyama H, Ino K, Terauchi M, Yamamoto E, Nawa A, et al: Twist expression in patients with cervical cancer is associated with poor disease outcome. Ann Oncol 2008; 19: 81-85.
26. Hosono S, Kajiyama H, Terauchi M, Shibata K, Ino K, Nawa A, et al: Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients. Br J Cancer 2007; 96: 314-320.
27. Kajiyama H, Hosono S, Terauchi M, Shibata K, Ino K, Yamamoto E, et al: Twist expression predicts poor clinical outcome of patients with clear cell carcinoma of the ovary. Oncology 2006; 71: 394-401.
28. Martin TA, Goyal A, Watkins G, Jiang WG: Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol 2005; 12: 488-496.
29. Zhang Z, Xie D, Li X, Wong YC, Xin D, Guan XY, et al: Significance of TWIST expression and its association with E-cadherin in bladder cancer. Hum Pathol 2007; 38: 598-606.
30. Ou DL, Chien HF, Chen CL, Lin TC, Lin LI: Role of Twist in head and neck carcinoma with lymph node metastasis. Anticancer Res 2008; 28: 1355-1359.
31. Di Costanzo A, Troiano A, di Martino O, Cacace A, Natale CF, Ventre M, et al: The p63 protein isoform ΔNp63α modulates Y-box binding protein 1 in its subcellular distribution and regulation of cell survival and motility genes. J Biol Chem 2012; 287: 30170-30180.
32. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Nozoe T, Yasumoto K: Expression of the p53 family in lung cancer. Anticancer Res 2006; 26: 1785-1790.
33. Uramoto H, Yamada S, Hanagiri T: Immunohistochemical staining with ΔNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung. Anticancer Res 2010; 30: 4717-4720.
34. Xia H, Ooi LL, Hui KM: MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology 2013; 58: 629-641.
35. Singh A, Settleman J: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-4751.
36. Christiansen JJ, Rajasekaran AK: Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006; 66: 8319-8326.